公开(公告)号：US20240170097A1

公开(公告)日：2024-05-23

申请号：US18420953

申请日：2024-01-24

Applicant: NEC Corporation

Inventor： Brandon MALONE ,  Jun CHENG

IPC: G16B30/20 ,  G16B5/20 ,  G16B20/40 ,  G16B40/20

CPC classification number: G16B30/20 ,  G16B5/20 ,  G16B20/40 ,  G16B40/20

Abstract: A computer-implemented method of selecting one or more amino acid sequences for inclusion in a vaccine from a set of predicted immunogenic candidate amino acid sequences includes identifying an immune profile response value for each candidate amino acid sequence with respect to each one of a plurality of sample components of an immune profile. The immune profile response value represents whether the respective candidate amino acid sequence results in an immune response for the sample components of the immune profile. A plurality of immune profiles are retrieved for a population. A plurality of representative immune profiles are generated for the population. The representative immune profiles overlap with the sample components of the immune profiles. The one or more amino acid sequences for inclusion in the vaccine that minimises a likelihood of no immune response for each representative immune profile, based on the immune profile response values, are selected.

公开(公告)号：US20240161872A1

公开(公告)日：2024-05-16

申请号：US18424042

申请日：2024-01-26

Applicant: NEC Corporation

Inventor： Brandon MALONE ,  Jun CHENG

IPC: G16B30/20 ,  G16B5/20 ,  G16B20/40 ,  G16B40/20

CPC classification number: G16B30/20 ,  G16B5/20 ,  G16B20/40 ,  G16B40/20

Abstract: A computer-implemented method of selecting one or more amino acid sequences for inclusion in a vaccine from a set of predicted immunogenic candidate amino acid sequences includes identifying an immune profile response value for each candidate amino acid sequence with respect to each one of a plurality of sample components of an immune profile. The immune profile response value represents whether the respective candidate amino acid sequence results in an immune response for the sample components of the immune profile. A plurality of immune profiles are retrieved for a population. A plurality of representative immune profiles are generated for the population. The representative immune profiles overlap with the sample components of the immune profiles. The one or more amino acid sequences for inclusion in the vaccine that minimises a likelihood of no immune response for each representative immune profile, based on the immune profile response values, are selected.

公开(公告)号：US20240161871A1

公开(公告)日：2024-05-16

申请号：US18422250

申请日：2024-01-25

Applicant: NEC Corporation

Inventor： Brandon MALONE ,  Jun CHENG

IPC: G16B30/20 ,  G16B5/20 ,  G16B20/40 ,  G16B40/20

CPC classification number: G16B30/20 ,  G16B5/20 ,  G16B20/40 ,  G16B40/20

Abstract: A computer-implemented method of selecting one or more amino acid sequences for inclusion in a vaccine from a set of predicted immunogenic candidate amino acid sequences includes identifying an immune profile response value for each candidate amino acid sequence with respect to each one of a plurality of sample components of an immune profile. The immune profile response value represents whether the respective candidate amino acid sequence results in an immune response for the sample components of the immune profile. A plurality of immune profiles are retrieved for a population. A plurality of representative immune profiles are generated for the population. The representative immune profiles overlap with the sample components of the immune profiles. The one or more amino acid sequences for inclusion in the vaccine that minimises a likelihood of no immune response for each representative immune profile, based on the immune profile response values, are selected.

公开(公告)号：US20210391031A1

公开(公告)日：2021-12-16

申请号：US17281707

申请日：2019-11-20

Applicant: NEC CORPORATION

Inventor： Brandon MALONE ,  Kousuke ONOUE ,  Yoshiko YOSHIHARA

IPC: G16B20/20 ,  G16B20/30 ,  G16B30/10 ,  G16B40/20

Abstract: A method of ranking epitopes derived from neoantigens as targets for personalized immunotherapy includes collecting candidate epitopes based on patient data of a cancer patient. A set of scores are calculated for each of the candidate epitopes, each of the scores in a respective one of the sets for a respective one of the candidate epitopes representing an independent measure of a likelihood of the respective one of candidate epitopes to elicit an immune response in the cancer patient. The scores in each of the sets of scores are combined into a single score for each of the candidate epitopes. The single scores for the candidate epitopes in each case reflect an overall likelihood of eliciting the immune response in the patient. The candidate epitopes are ranked using the single scores for the immunotherapy.